In-Depth Examination Of 11 Analyst Recommendations For Amgen
Portfolio Pulse from Benzinga Insights
The article provides an in-depth examination of 11 analyst recommendations for Amgen (NASDAQ:AMGN) over the past three months. Analysts have varied opinions, with ratings ranging from bullish to bearish. The average 12-month price target for Amgen has increased by 4.98% to $338.45. Key financial metrics such as revenue growth, net margin, ROE, and ROA are highlighted, along with challenges in debt management.
October 14, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Amgen has received mixed analyst ratings over the past three months, with a slight increase in the average price target. The company's financial metrics show strong profitability but challenges in debt management.
The article discusses various analyst ratings for Amgen, showing a mix of bullish and bearish sentiments. The average price target has increased, indicating some positive outlook. However, financial metrics reveal both strengths in profitability and challenges in debt management, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100